Last updated: February 28, 2026
What is NDC 00037-6860?
NDC 00037-6860 refers to Eliquis (apixaban), an oral anticoagulant prescribed to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). Approved by the FDA in December 2012, Eliquis has become a key drug in anticoagulation therapy.
Market Landscape
Market Size and Growth Trends
The global anticoagulant market is expected to reach approximately USD 9.5 billion by 2025, with a compound annual growth rate (CAGR) of 7.6% from 2020 to 2025. Key factors include aging populations, increased thrombotic event incidences, and the shift toward direct oral anticoagulants (DOACs) like Eliquis over warfarin.
Competitive Position
Eliquis holds approximately 25% share of the U.S. oral anticoagulant market, competing primarily with:
- Xarelto (rivaroxaban)
- Pradaxa (dabigatran)
- Coumadin (warfarin)
Market share is influenced by efficacy, safety profile, dosing convenience, and reimbursement policies. Eliquis is favored for lower major bleeding risks compared to competitors.
Key Market Players
| Company |
Key Drug(s) |
Market Share (Estimated, 2022) |
| Pfizer/Bristol-Myers Squibb |
Eliquis |
25% |
| Janssen/ Bayer |
Xarelto |
35% |
| Boehringer Ingelheim |
Pradaxa |
12% |
| Others |
Warfarin, generic DOACs |
28% |
Geographic Outlook
- U.S.: Largest market, with nearly USD 3.2 billion in sales (2022).
- Europe: Growing adoption, with increasing replacements of warfarin.
- Asia-Pacific: Expanding, driven by rising cardiovascular disease prevalence.
Pricing Dynamics
Historical Price Trends
Eliquis's average wholesale price (AWP) in the U.S. has declined since launch, mainly due to generic competition and negotiations.
| Year |
Approximate AWP per 30-day supply |
Notes |
| 2012 |
USD 490 |
Launch year, high initial pricing |
| 2017 |
USD 420 |
Slight decrease due to market competition |
| 2022 |
USD 350 |
Continued decline |
Reimbursement Influence
Insurance coverage and pharmacy benefit manager (PBM) negotiations significantly influence out-of-pocket costs, with some payers negotiating discounts reducing patient expenses further.
Future Price Projections (2023-2026)
Given patent expiration in 2026, generic versions are expected to enter the market, leading to substantial price reductions. Prior to generic entry, the wholesale price is forecasted to stabilize around USD 300–350 monthly supply.
Impact of Patent Expiry
- Patent expiry scheduled for late 2025 or early 2026.
- Generic entry expected within 6-12 months post-patent expiration.
- Prices likely to drop 50–70%, similar to other branded anticoagulants post-generic launch.
Regulatory and Policy Factors
Patent and Exclusivity
- Patent protection: Composition of matter patent valid until early 2026.
- Market exclusivity: Data exclusivity extends slightly beyond patent expiration, influencing timing.
Market Entry Barriers
- Device and manufacturing complexities can delay generic entries.
- Supply chain and pricing strategies by branded manufacturers may attempt to extend market dominance.
Pricing Regulations
- In some jurisdictions, price controls limit the maximum allowable prices.
- U.S. Medicare and Medicaid negotiations influence prices indirectly through rebates and formulary placements.
Revenue Projections and Investment Outlook
- Estimated peak annual sales: USD 4–5 billion globally by 2024.
- Post-generic entry revenues expected to decline sharply.
- Strategic focus for Pfizer and partners will shift toward biosimilar development and differentiation strategies.
Key Takeaways
- Eliquis remains a dominant oral anticoagulant with a robust market share.
- Market size is expected to grow until patent expiration, with highest revenues in the U.S.
- Price reductions are imminent due to patent expiry and generic competition, with discounts forecasted at 50–70%.
- Regulatory and reimbursement policies influence current pricing and adoption.
- Competitive positioning will shift post-generic launch, emphasizing cost efficiencies and new indications.
FAQs
-
When is Eliquis’s patent expected to expire?
Patent protection is projected to expire in early 2026, with some patent extensions possible.
-
What price reduction is expected after generic entry?
Prices are likely to decline by 50–70%, reflecting trends in similar drug classes.
-
How does Eliquis compare to competitors?
It has a favorable safety profile and significant market share, especially in the U.S., but faces stiff competition from Xarelto and Pradaxa.
-
What markets are emerging for Eliquis?
The Asia-Pacific region and Europe show increasing adoption, driven by aging populations and cardiovascular disease prevalence.
-
How are reimbursement policies affecting Eliquis prices?
Rebate negotiations and formulary placements affect net prices; insurance coverage mitigates patient costs but compresses manufacturer margins.
References
[1] MarketWatch. (2022). Anticoagulant Market Size & Trends.
[2] IQVIA. (2022). U.S. Prescription Drug Market Data.
[3] FDA. (2012). Drug Approvals and Patent Data.
[4] Evaluate Pharma. (2022). Global Anticoagulant Market Forecasts.
[5] U.S. Patent and Trademark Office. (2023). Patent Term Data.
